TCF1 (transcription factor 1) encoding hepatocyte nuclear factor 1a (HNF1a) is mutated in 50% of liver cell adenomas, a benign tumor closely associated with oral contraceptive use. These genetic alterations inactivate both alleles, leading to the absence of wild-type HNF1a expression in liver cell adenomas. To search for a role of HNF1a in other hormone-related neoplasias, we screened for HNF1a mutations in a series of 36 endometrial carcinomas, 29 breast carcinomas and 20 ovarian epithelial tumors. HNF1a mutations were identified in 4/ 36 (11%) of endometrial tumors. No mutation was found in ovarian and breast tumors. HNF1a mutations were somatic in all cases, monoallelic in three cases and biallelic in one case. These results suggest that HNF1a may contribute to endometrial carcinogenesis through complete HNF1a inactivation like in liver cell adenoma or by haploinsufficiency like in MSI-H colorectal cancer.
Inserm U490, Laboratoire de Toxicologie Mole´culaire, 45 rue des Saints Pe`res, 75006 Paris, France TCF1 (transcription factor 1) encoding hepatocyte nuclear factor 1a (HNF1a) is mutated in 50% of liver cell adenomas, a benign tumor closely associated with oral contraceptive use. These genetic alterations inactivate both alleles, leading to the absence of wild-type HNF1a expression in liver cell adenomas. To search for a role of HNF1a in other hormone-related neoplasias, we screened for HNF1a mutations in a series of 36 endometrial carcinomas, 29 breast carcinomas and 20 ovarian epithelial tumors. HNF1a mutations were identified in 4/ 36 (11%) of endometrial tumors. No mutation was found in ovarian and breast tumors. HNF1a mutations were somatic in all cases, monoallelic in three cases and biallelic in one case. These results suggest that HNF1a may contribute to endometrial carcinogenesis through complete HNF1a inactivation like in liver cell adenoma or by haploinsufficiency like in MSI-H colorectal cancer. Keywords: endometrial cancer; ovarian cancer; breast cancer; hepatocyte nuclear factor 1; HNF1a; gene mutation; liver cell adenoma; microsatellite instability; MSI-H TCF1 (transcription factor 1) encodes hepatocyte nuclear factor 1 (HNF1a), a transcription factor implicated in hepatocyte differentiation and required for the liverspecific expression of several genes, including b-fibrinogen, albumin and a1-antitrypsin (Courtois et al., 1987; Frain et al., 1989; Baumhueter et al., 1990; Cereghini et al., 1990; Chouard et al., 1990) . In 1996, Yamagata et al. (1996) identified germline mutations of HNF1a in individuals affected with maturity-onset diabetes of the young type 3 (MODY3, OMIM #600496). MODY3 is a rare, dominantly inherited subtype of non-insulin-dependent diabetes mellitus characterized by early onset, usually before the age of 25, and a primary defect in insulin secretion. Biallelic HNF1a inactivation has been identified in 50% of liver cell adenomas. Somatic mutations were present in 90% of the cases and germline mutations were found in the remaining cases, corresponding to MODY3 patients, who developed liver cell adenomas with inactivation of the second allele in tumor cells (Bluteau et al., 2002; Bacq et al., 2003) . Liver cell adenomas are benign tumors associated with oral contraceptive use in 90% of the cases, suggesting a role of estrogen in cell proliferation related to HNF1a inactivation. Furthermore, HNF1a mutations were identified in two well-differentiated hepatocellular carcinoma (HCC) occurring in otherwise normal liver (i.e. 5% of all HCC cases). In liver tumors, all HNF1a mutations were observed in the 5 0 part of the gene coding for the dimerization and the homeodomain of HNF1a. These results indicate that HNF1a inactivation is an important genetic event in the occurrence of human liver adenoma and may be an early step in development of some HCCs through a biallelic inactivation (Bluteau et al., 2002; Bacq et al., 2003; Laurent-Puig et al., 2003) . On the other hand, monoallelic HNF1a mutations were observed in 23% of colon cancer cases associated with microsatellite instability phenotype (MSI-H). In colon cancer, all these mutations, consisting in one base-pair deletion or insertion, were observed in the polymorphic poly-cytosin (C) 8 or (C) 9 tract leading to a frameshift at codon 291 (P291fsX341) (Laurent-Puig et al., 2003) .
Since the highest rate of HNF1a mutations were identified in liver cell adenomas, which are closely related to oral contraceptive use, we searched for HNF1a alterations in other hormone-related tumors (Henderson et al., 1988) . To test this hypothesis, we selected endometrial, breast and ovarian primary epithelial tumors to search for HNF1a inactivation.
A series of 36 endometrial carcinomas were analysed for HNF1a mutations. The main clinical and histopathological characteristics are described in Table 1 . HNF1a mutations were screened by direct sequencing of all exons with their intronic boundaries as described by Bluteau et al. (2002) . Five mutations were identified in four endometrial tumors (Table 2) . In all cases, the somatic origin of the mutations was demonstrated by the lack of HNF1a alteration in the corresponding nontumor DNAs. In case 28T, a biallelic mutation of TCF1 was observed. The first allele was inactivated by a somatic transversion in the consensus sequence of the exon 5 acceptor splicing site (IVS5-1G4T). On the other allele, an interstitial gene deletion was evidenced. This deletion was mapped by gene SNP analyses and encompassed at least exons 1-3 of the HNF1a gene ( Figure 1 ). These results predicted the absence of HNF1a normal protein in tumor 28T.
In endometrial tumor 25T, two somatic point mutations, one transversion and one transition, were found at nucleotides 465 and 502, respectively (Table 2 and Figure 2 ). These mutations altered amino acid 155 (K155N) and 168 (R168C) in the pou-specific domain, which is important for the recognition by HNF1a of specific DNA targets in promoters of the genes regulated by this transcription factor. These two amino acids are conserved through evolution in chicken, rat and mouse species suggesting their importance in the HNF1a function, but crystallographic HNF1a structure did not show a direct contact between K155 or R168 amino acids with DNA (Chi et al., 2002) . Interestingly, allele-specific amplification followed by sequence analysis showed that the two mutations were located on the same allele. We did not find any alteration of the second HNF1a allele since no other point mutation or loss of heterozygosity (LOH) was observed at the DNA level. Furthermore, RT-PCR product sequencing of the TCF1 transcript showed that the expression level of the normal and the mutated alleles was similar. Surprisingly, K155N and R168C mutations have not been previously observed in MODY3 patients or in somatic HNF1a alterations found in liver cell adenomas or in colon cancer (Figure 3 ). This In endometrial tumors 2T and 40T, deletion of a cytosine in a poly-cytosin tract was observed at positions 865-872 and 1039-1042, respectively. The mutation in tumor 2T occurred in a polymorphic polycytosin (C) 8 /(C) 9 tract frequently mutated in MODY3 patients and in MSI-H colon cancer leading to P291fsX316. We determined the MSI status in the series of endometrial tumors by immunohistochemistry. It was performed on 4-mm sections of alcohol/formaldehyde/ acetic acid-fixed paraffin-embedded tumor tissues using monoclonal antibodies G168-15 for hMLH1 (Pharmingen) and clone FE11 for hMSH2 (Oncogene Research Products). Both antibodies were applied for 1 h at room temperature at a 1% dilution in TechMate Horizon automatic immunostainer (Dako). The Biogenex supersensitive kit (Menarini Diagnostics) with 3,3 0 -diaminobenzidine was used for the detection of the immunostaining. Sections were counterstained with Mayer's hematoxylin. Tumor sections were evaluated for nuclear immunostaining. Tumors were scored as positive or negative. Any evidence of nuclear staining, even in small foci, was considered as positive. Positive hMSH2 immunostaining was observed in all cases ( Table 1) . Loss of hMLH1 expression was observed in Figure 3 summary of HNF1a mutations found in adenoma and HCC (Bluteau et al., 2002) , MSI-H colon cancer (Laurent-Puig et al., 2003) , endometrial tumors (present work) and MODY3 (Ellard, 2000) . HNF1a mutations are represented by triangles, rhombus or boxes in white (germline), in black (biallelic somatic) and in gray (monoallelic somatic). For recurrent mutations, number of cases described is indicated HNF1a alterations in gynecological cancers S Rebouissou et al four cases including the 2T case, who was heterozygous at poly-cytosin (C) 8 /(C) 9. The deletion observed in this case occurred at the poly(C) 8 allele leading to a frameshift at codon 291. In case 40T, the cytosin deletion occurred in a poly-cytosin (C) 4 leading to a frameshift at codon 348 (L348fsX363), but no MSI-H phenotype was observed. Similar to colon cancer and in contrast with liver cell adenoma, we did not identify a second mutation on the other allele. The monoallelic origin of the mutation in case 2T was confirmed by sequencing the TCF1 mRNA after RT-PCR amplification, which confirmed the expression of both alleles. These results suggest that these truncated HNF1a proteins may have a dominant negative function in endometrial carcinogenesis. Finally, no association was found between the occurrence of HNF1a mutation and histoclinical characteristics of the patients. In order to evaluate the expression level of TCF1 in endometrial tissues, we performed quantitative RT-PCR in tumor and normal endometrial samples. RNA was extracted from the 36 screened endometrial tumors and two normal endometrial tissues. In all, 22/36 tumor RNAs and both normal RNAs met the criteria of quality to be used in real-time RT-PCR experiments. Analysis of the TCF1 level of transcription showed deep downregulation in five tumors including the biallelic mutated 28T case and four nonmutated tumors (Figure 4) . This result suggests that, apart of HNF1 biallelic mutations, other mechanisms of HNF1a inactivation may be involved in endometrial tumors as hypermethylation of HNF1 promoter. When expressed, the TCF1 RNA expression level in endometrial tumors was identical to the level observed in human normal liver. Samples 2T and 25T, mutated on one HNF1a allele, showed a 10-fold higher HNF1a mRNA level of expression when compared with normal tissues. In nonmutated tumor samples, HNF1a mRNA level of expression was also higher than in normal tissues. Subsequently, we quantified the expression level of three genes known to be regulated by HNF1a in liver (fatty acid-binding protein 1, FABP1; UDP glycosyltransferase 2 family polypeptide B7, UGT2B7; dopa decarboxylase, DDC) (Aguanno et al., 1996; Akiyama et al., 2000; Ishii et al., 2000) . These targeted genes were not expressed in normal and tumor endometrial tissues, except in the 4T case, which showed concomitantly the highest level of TCF1 expression and a measurable expression of the HNF1a targeted genes (data not shown). These results suggest that HNF1a alterations in endometrial tumors do not target the same genes as in liver when HNF1a is expressed at a similar level. HNF1a-regulated genes in endometrial tissues remain to be identified in order to appreciate the impact of monoallelic HNF1a mutations on genes and pathways that may be important in endometrial carcinogenesis.
A series of 29 breast carcinomas and 20 ovarian epithelial tumors were analysed for TCF1 mutations. Patients presenting invasive ductal carcinoma had a mean age of 59 years (range 33-80) and the mean diameter of the tumor was 2.5 cm (range 0.8-11). Histological grades of the tumors were as follows: SBR I in four cases, SBR II in 19 and SBR III in six cases. All tumors were infiltrating and lymph nodes were positive in half of the cases. Expressions of estrogen and progesterone receptors were found in 21/29 and 12/29 cases, respectively. cERBB2 overexpression was found in 5/29 cases. Among the 20 ovarian tumors analysed, two were benign (serous and mucinous cystadenomas), and the remaining 18 cases were ovarian carcinomas. The mean age of patients presenting ovarian cancer was 62 years (range 38-92). Tumors were well, moderate and poorly differentiated in nine, seven and two cases, respectively. No mutation of TCF1 gene was found in these series of breast and ovarian tumors. Although, based on our previous works (Bluteau et al., 1999a, b; Laurent-Puig et al., 2001) , the sensitivity of our DNA sequencing method enables one to detect one mutated allele among five normal alleles, these results do not support the presence of a structural HNF1a alteration in the main tumor clone cells.
In conclusion, we identified HNF1a structural alterations in 11% of endometrial carcinomas but no mutations were found in breast and ovarian tumors. Among the mutated tumors, HNF1a alterations were biallelic in one case and monallelic in three cases. These results indicate that HNF1a alterations may participate in carcinogenesis in a subset of endometrial cancer Figure 4 Level of TCF1 mRNA expression in normal endometrial tissues (white), TCF1 mutated tumors (black) and nonmutated tumors (gray). A 1 mg of total RNA was reverse transcribed in a final volume of 100 ml using the high-capacity archive kit and random hexamers (Applied Biosystems). For each sample, 5 ml of cDNA (diluted 1 : 5), corresponding to approximately 10 ng of reverse-transcribed RNA, was analyzed by TaqMan PCR analysis, in duplicate, using the ABI PRISM s 7900HT Sequence Detection System (Applied Biosystems). Predeveloped sequence detection reagents specific for human r18S and TCF1 (Applied Biosystems), including forward and reverse primers as well as a fluorogenic TaqMan FAM-labeled NFQ MGB hybridization probe were used in a 20 ml TaqMan universal PCR 1X master mix. The relative amount of TCF1 mRNA in the samples was determined using the 2 ÀDDCT method (Livak and Schmittgen, 2001) , where DDCT ¼ (CT TCF1 ÀCTr18s) sample -(CT TCF1 -CTr18s) calibrator .
Expression results of a gene were normalized to internal control ribosomal 18S and relatively to a calibrator, consisting in the mean expression level of the corresponding gene in nontumor samples normalized to internal control ribosomal 18S HNF1a alterations in gynecological cancers S Rebouissou et al through various mechanisms including complete inactivation, like in liver cell adenomas, and possible dominant negative effect or haploinsufficiency, like in colon cancer. Abbreviations HNF1, hepatocyte nuclear factor 1a; TCF1, transcription factor 1; MODY3, maturity-onset diabetes of the young type 3; MSI-H, microsatellite instability high; MSS, microsatellite stable; LOH, loss of heterozygosity.
